The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will convene July 22 to discuss a pair of recent issues related to COVID-19 vaccines.

The agenda released ahead of the meeting includes discussion of the reported risk of Guillain-Barré Syndrome from the Johnson & Johnson vaccine, which recently prompted the Food and Drug Administration to update its vaccine recipient and vaccination provider fact sheets.

The committee will also discuss clinical considerations for additional vaccine doses in immunocompromised individuals; this represents the first formal consideration of boosters for individuals who have already completed a full dose regimen of the COVID-19 vaccines.

Related News Articles

Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and…
Headline
The Centers for Disease Control and Prevention Friday updated its COVID-19 infection control guidance for U.S. health care settings based on current…
Headline
AHA will co-host a Sept. 27 Facebook Live event with AdventHealth on the importance of getting children vaccinated and boosted against COVID-19, which will…
Headline
Insured and uninsured Americans can receive the new bivalent Pfizer or Moderna COVID-19 booster and other COVID-19 vaccines at no cost as long as the federal…